Cyber knife: A new technology in the treatment of high grade gliomas

L. Fariselli, G. Broggi, M. De Santis, F. Ghielmetti, A. Bergantin, M. Possanzini, I. Milanesi

Research output: Contribution to journalArticle

Abstract

PURPOSE: To evaluate the efficacy of radiosurgery (SRS) and hypofractionated radiotherapy (FSRT) performed as reirradiation or boost in 31 patients with recurrent high grade gliomas (HGG) using Cyberknife radiotherapy system. PATIENTS AND METHODS: Between April 2004 and July 2006, 31 patients with HGG were treated with FSRT or SRS as boost or reirradiation in a single institution using Cyberknife radiosurgery system. All patients suffered from WHO grade 3-4 gliomas. External beam radiotherapy was performed in all patients, in 9 patients SRS with Cyberknife was added as boost, 22 patients were treated at recurrence with FSRT. The median time between primary radiotherapy and reirradiation was 10 months. A median dose of 12 Gy in single shoot was prescribed as boost after EBRT, FSRT was performed with a median dose of 24 Gy in 3 fractions. RESULTS: Median overall survival after primary diagnosis was 16 months in Glioblastoma Multiforme (GEM) group and not yet reached in anaplastic astrocytoma group; a median survival time of 9.5 month was observed in patient's group treated with boost after EBRT. The radiotherapy schedule was well tolerated; 2 radiation's necrosis were observed in a FSRT group. CONCLUSION: FSRT and SRS are well tolerated. Our study suggests that FSRT is more appropriate as treatment option at tumour recurrence and may be more effective in patients with recurrent gliomas than SRS boost.

Original languageEnglish
Pages (from-to)173-178
Number of pages6
JournalRivista Medica
Volume13
Issue number4
Publication statusPublished - Dec 2007

Fingerprint

Glioma
Technology
Radiotherapy
Radiosurgery
Therapeutics
Recurrence
Survival
Astrocytoma
Glioblastoma
Appointments and Schedules
Necrosis
Radiation
Re-Irradiation
Neoplasms

Keywords

  • Cyberknife
  • High grade gliomas
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fariselli, L., Broggi, G., De Santis, M., Ghielmetti, F., Bergantin, A., Possanzini, M., & Milanesi, I. (2007). Cyber knife: A new technology in the treatment of high grade gliomas. Rivista Medica, 13(4), 173-178.

Cyber knife : A new technology in the treatment of high grade gliomas. / Fariselli, L.; Broggi, G.; De Santis, M.; Ghielmetti, F.; Bergantin, A.; Possanzini, M.; Milanesi, I.

In: Rivista Medica, Vol. 13, No. 4, 12.2007, p. 173-178.

Research output: Contribution to journalArticle

Fariselli, L, Broggi, G, De Santis, M, Ghielmetti, F, Bergantin, A, Possanzini, M & Milanesi, I 2007, 'Cyber knife: A new technology in the treatment of high grade gliomas', Rivista Medica, vol. 13, no. 4, pp. 173-178.
Fariselli L, Broggi G, De Santis M, Ghielmetti F, Bergantin A, Possanzini M et al. Cyber knife: A new technology in the treatment of high grade gliomas. Rivista Medica. 2007 Dec;13(4):173-178.
Fariselli, L. ; Broggi, G. ; De Santis, M. ; Ghielmetti, F. ; Bergantin, A. ; Possanzini, M. ; Milanesi, I. / Cyber knife : A new technology in the treatment of high grade gliomas. In: Rivista Medica. 2007 ; Vol. 13, No. 4. pp. 173-178.
@article{c947b3498e0f432382a280d1115e14f7,
title = "Cyber knife: A new technology in the treatment of high grade gliomas",
abstract = "PURPOSE: To evaluate the efficacy of radiosurgery (SRS) and hypofractionated radiotherapy (FSRT) performed as reirradiation or boost in 31 patients with recurrent high grade gliomas (HGG) using Cyberknife radiotherapy system. PATIENTS AND METHODS: Between April 2004 and July 2006, 31 patients with HGG were treated with FSRT or SRS as boost or reirradiation in a single institution using Cyberknife radiosurgery system. All patients suffered from WHO grade 3-4 gliomas. External beam radiotherapy was performed in all patients, in 9 patients SRS with Cyberknife was added as boost, 22 patients were treated at recurrence with FSRT. The median time between primary radiotherapy and reirradiation was 10 months. A median dose of 12 Gy in single shoot was prescribed as boost after EBRT, FSRT was performed with a median dose of 24 Gy in 3 fractions. RESULTS: Median overall survival after primary diagnosis was 16 months in Glioblastoma Multiforme (GEM) group and not yet reached in anaplastic astrocytoma group; a median survival time of 9.5 month was observed in patient's group treated with boost after EBRT. The radiotherapy schedule was well tolerated; 2 radiation's necrosis were observed in a FSRT group. CONCLUSION: FSRT and SRS are well tolerated. Our study suggests that FSRT is more appropriate as treatment option at tumour recurrence and may be more effective in patients with recurrent gliomas than SRS boost.",
keywords = "Cyberknife, High grade gliomas, Stereotactic radiosurgery",
author = "L. Fariselli and G. Broggi and {De Santis}, M. and F. Ghielmetti and A. Bergantin and M. Possanzini and I. Milanesi",
year = "2007",
month = "12",
language = "English",
volume = "13",
pages = "173--178",
journal = "Rivista Medica",
issn = "1127-6339",
publisher = "New Magazine Edizioni S.r.l.",
number = "4",

}

TY - JOUR

T1 - Cyber knife

T2 - A new technology in the treatment of high grade gliomas

AU - Fariselli, L.

AU - Broggi, G.

AU - De Santis, M.

AU - Ghielmetti, F.

AU - Bergantin, A.

AU - Possanzini, M.

AU - Milanesi, I.

PY - 2007/12

Y1 - 2007/12

N2 - PURPOSE: To evaluate the efficacy of radiosurgery (SRS) and hypofractionated radiotherapy (FSRT) performed as reirradiation or boost in 31 patients with recurrent high grade gliomas (HGG) using Cyberknife radiotherapy system. PATIENTS AND METHODS: Between April 2004 and July 2006, 31 patients with HGG were treated with FSRT or SRS as boost or reirradiation in a single institution using Cyberknife radiosurgery system. All patients suffered from WHO grade 3-4 gliomas. External beam radiotherapy was performed in all patients, in 9 patients SRS with Cyberknife was added as boost, 22 patients were treated at recurrence with FSRT. The median time between primary radiotherapy and reirradiation was 10 months. A median dose of 12 Gy in single shoot was prescribed as boost after EBRT, FSRT was performed with a median dose of 24 Gy in 3 fractions. RESULTS: Median overall survival after primary diagnosis was 16 months in Glioblastoma Multiforme (GEM) group and not yet reached in anaplastic astrocytoma group; a median survival time of 9.5 month was observed in patient's group treated with boost after EBRT. The radiotherapy schedule was well tolerated; 2 radiation's necrosis were observed in a FSRT group. CONCLUSION: FSRT and SRS are well tolerated. Our study suggests that FSRT is more appropriate as treatment option at tumour recurrence and may be more effective in patients with recurrent gliomas than SRS boost.

AB - PURPOSE: To evaluate the efficacy of radiosurgery (SRS) and hypofractionated radiotherapy (FSRT) performed as reirradiation or boost in 31 patients with recurrent high grade gliomas (HGG) using Cyberknife radiotherapy system. PATIENTS AND METHODS: Between April 2004 and July 2006, 31 patients with HGG were treated with FSRT or SRS as boost or reirradiation in a single institution using Cyberknife radiosurgery system. All patients suffered from WHO grade 3-4 gliomas. External beam radiotherapy was performed in all patients, in 9 patients SRS with Cyberknife was added as boost, 22 patients were treated at recurrence with FSRT. The median time between primary radiotherapy and reirradiation was 10 months. A median dose of 12 Gy in single shoot was prescribed as boost after EBRT, FSRT was performed with a median dose of 24 Gy in 3 fractions. RESULTS: Median overall survival after primary diagnosis was 16 months in Glioblastoma Multiforme (GEM) group and not yet reached in anaplastic astrocytoma group; a median survival time of 9.5 month was observed in patient's group treated with boost after EBRT. The radiotherapy schedule was well tolerated; 2 radiation's necrosis were observed in a FSRT group. CONCLUSION: FSRT and SRS are well tolerated. Our study suggests that FSRT is more appropriate as treatment option at tumour recurrence and may be more effective in patients with recurrent gliomas than SRS boost.

KW - Cyberknife

KW - High grade gliomas

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=34547309564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547309564&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34547309564

VL - 13

SP - 173

EP - 178

JO - Rivista Medica

JF - Rivista Medica

SN - 1127-6339

IS - 4

ER -